Programs

Entrada Therapeutics is working on several intracellular targets and programs that address devastating diseases with the hopes of transforming patient lives

Entrada’s proprietary intracellular biologics platform enables the intracellular delivery of biologics to address devastating diseases and transform patients’ lives. This platform can deliver a variety of modalities, allowing for the development of programs across several intracellular target classes.

Intracellular Enzyme Replacement Therapy

Discovery/PoC
Preclinical
IND-enabling
Phase I/II
Lead IC-ERT
IC-ERT #2
Other IC-ERTs

Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell. By delivering the enzyme directly into the cell, Entrada can address intracellular enzyme deficiencies in a safe, predictable and controlled manner.

Entrada’s lead program targets a rare, fatal, mitochondrial disease caused by mutations in a gene that codes for an intracellular enzyme. As a result of this defective gene, toxic metabolites accumulate in patients causing significant gastrointestinal and neuromuscular damage.

Protein-Protein Interaction Inhibitors

Discovery/PoC
Preclinical
IND-enabling
Phase I/II
PPI Program #1
PPI Program #2
PPI Program #3
PPI Program #4

Intracellular protein-protein interactions (PPIs) is an emerging class of undruggable targets. Targeting intracellular PPIs with PPI inhibitors represents a significant untapped clinical and commercial opportunity for Entrada.

Additional Applications

Discovery/PoC
Preclinical
IND-enabling
Phase I/II

Entrada’s platform technology can also be used to carry other cargos into the cell. We are actively exploring several additional applications beyond our IC-ERT and PPI inhibitor programs.